MedPath

A Clinical Trial of IntensiVE Dialysis

Phase 4
Completed
Conditions
Uremia
Renal Replacement Therapy
Renal Dialysis
End Stage Renal Disease
End Stage Kidney Disease
Interventions
Procedure: haemodialysis
Registration Number
NCT00649298
Lead Sponsor
The George Institute
Brief Summary

This study will assess clinical outcomes of extended weekly hours of haemodialysis (\>= 24 hours per week) compared with standard hours of haemodialysis (\<=18 hours/week) in people with ESKD.

Detailed Description

A rapidly increasing volume of observational data suggests substantial benefits may be associated with an increased duration of dialysis. As well as improved quality of life, improved functioning and beneficial changes in a variety of laboratory parameters, it has been suggested that extended dialysis sessions might reduce mortality and major morbidity. Uncontrolled data from centres that have been providing extended dialysis shows dramatically lower mortality rates compared to those observed in centres providing standard duration dialysis. Recent analyses of extended dialysis conclude that the savings achieved in drug and hospitalization costs may lead to an overall reduction in costs compared with traditional forms of dialysis.

In this trial, we propose to examine the effects of extended dialysis (24 hours weekly or more) compared to standard dialysis (18 hours or less weekly) in patients with ESKD. The proposed study is a multi-centre, open label, randomised, controlled trial.

The study began with a pilot phase which was converted to the current main study on the receipt of peer-reviewed funding for the full study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
200
Inclusion Criteria
  1. Incident or prevalent patients requiring maintenance haemodialysis therapy for ESKD
  2. Aged 18 years or older
  3. Undergoing dialysis for 18 hours per week or less
  4. Suitable for either extended or standard dialysis in the view of the treating physician
  5. Agreeable to randomisation
Exclusion Criteria
  1. Life expectancy of less than 6 months
  2. Definite plans to undergo renal transplantation within 12 months of entry to the study
  3. Inability to complete quality of life questionnaire
  4. Concomitant major illness that would limit assessments and followup
  5. High chance that the patient will not adhere to study treatment and follow up in the view of the treating physician.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
standard hourshaemodialysis18 or less hours per week of hemodialysis
extended hourshaemodialysis24 or more hours per week of hemodialysis
Primary Outcome Measures
NameTimeMethod
The primary end-point for this study is the difference in the change in quality of life between the two groups from randomisation to the 12 month follow-up as measured by the EQ-5D instrument.12 months from randomisation
Secondary Outcome Measures
NameTimeMethod
Quality of life and patient acceptability12 months
Changes in biochemical and haematological parameters12 months
Safety outcomes12 months
Costs associated with each intervention12 months
Survival and cardiovascular analyses12 months

Trial Locations

Locations (40)

Huaxi Hospital of Sichuan University

🇨🇳

Chengdu, Sichuan, China

Sydney Dialysis Centre

🇦🇺

Sydney, New South Wales, Australia

Sydney Adventist Hospital

🇦🇺

Sydney, New South Wales, Australia

Liverpool Hospital

🇦🇺

Sydney, New South Wales, Australia

St Michael's Hospital

🇨🇦

Toronto, Ontario, Canada

First Affiliated Hospital of Chinese PLA General Hospital

🇨🇳

Haidian District, Beijing, China

Sir Charles Gairdner Hospital

🇦🇺

Perth, Western Australia, Australia

UBC

🇨🇦

Vancouver, British Columbia, Canada

University Health Network

🇨🇦

Toronto, Ontario, Canada

Austin Hospital

🇦🇺

Melbourne, Victoria, Australia

Monash Medical Centre

🇦🇺

Melbourne, Victoria, Australia

The Canberra Hospital

🇦🇺

Canberra, Australian Capital Territory, Australia

RPAH/Concord

🇦🇺

Sydney, New South Wales, Australia

Gold Coast Hospital

🇦🇺

Gold Coast, Queensland, Australia

Nambour General Hospital

🇦🇺

Nambour, Queensland, Australia

Princess Alexandra Hospital

🇦🇺

Brisbane, Queensland, Australia

Royal Melbourne Hospital

🇦🇺

Melbourne, Victoria, Australia

Royal Brisbane Hospital

🇦🇺

Brisbane, Queensland, Australia

Royal Hobart Hospital

🇦🇺

Hobart, Tasmania, Australia

Beijing Hospital of Traditional Chinese Medicine

🇨🇳

Beijing, Beijing, China

Civil Aviation General Hospital

🇨🇳

Chaoyang District,, Beijing, China

Beijing Tongren Hospital

🇨🇳

Beijing, Beijing, China

Beijing Hospital

🇨🇳

Xicheng District, Beijing, China

China-Japan Friendship Hospital

🇨🇳

Chaoyang District, Beijing, China

Peking University People's Hospital

🇨🇳

Xicheng District, Beijing, China

Shenzhen Hospital of Peking University

🇨🇳

Shenzhen, Guangdong, China

Shijiazhuang First People's Hospital

🇨🇳

Shijiazhuang, Hebei, China

Fourth Hospital Affiliated to Hebei Medical University

🇨🇳

Shijiazhuang, Hebei, China

Zhengzhou University affiliated first hospital

🇨🇳

Zhengzhou, Henan, China

Third Hospital Affiliated to Hebei Medical University

🇨🇳

Shijiazhuang, Hebei, China

First Affiliated Hospital of Inner Mongolia, Baotou Medical College

🇨🇳

Baotou, Inner Mongolia, China

Fourth Hospital Affiliated to Jilin University (FAW General Hospital)

🇨🇳

Changchun, Jilin, China

Shanghai Ruijin Hospital

🇨🇳

Shanghai, Shanghai, China

Zhongda Hospital, Southeast University

🇨🇳

Nanjing, Jiangsu, China

The Chinese PLA Shanghai 85th Hospital

🇨🇳

Shanghai, Shanghai, China

Dalian Medical affiliated first hospital

🇨🇳

Dalian, Liaoning, China

The second affiliated hospital of Shanxi Medical University

🇨🇳

Taiyuan City, Shanxi, China

Auckland City Hospital

🇳🇿

Auckland, New Zealand

North Shore Hospital

🇳🇿

Auckland, New Zealand

Peking University First Hospital

🇨🇳

Xicheng District, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath